Next Article in Journal
Retrospective Analysis of Emotional Burden and the Need for Support of Patients and Their Informal Caregivers after Palliative Radiation Treatment for Brain Metastases
Next Article in Special Issue
Locoregional Management of Breast Cancer: A Chronological Review
Previous Article in Journal
Artificial Intelligence System for Predicting Prostate Cancer Lesions from Shear Wave Elastography Measurements
Previous Article in Special Issue
Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
Article

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

1
Department of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N4N2, Canada
2
Department of Oncology, Cross Cancer Institute, Edmonton, AB T6G1Z2, Canada
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Curr. Oncol. 2022, 29(6), 4224-4234; https://doi.org/10.3390/curroncol29060337
Received: 12 May 2022 / Revised: 8 June 2022 / Accepted: 10 June 2022 / Published: 11 June 2022
(This article belongs to the Special Issue Evolving Paradigm of Curative Intent Breast Cancer Management)
The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total pathological complete response (tpCR) rates (lack of residual invasive cancer in resected breast tissue and axillary nodes), of MYL-1401O to reference trastuzumab (TRZ) in the neoadjuvant setting for HER2+ early breast cancer (EBC) in Alberta, Canada. Neoadjuvant patients with HER2+ EBC treated with TRZ from November 2018–October 2019 and MYL-1401O from December 2019–September 2020 were identified. Logistic regression was used to control for variables potentially associated with tpCR: trastuzumab product, age, pre-operative T- and N-stage, grade, hormone receptor (HR)-status, HER2-status, chemotherapy regimen, and chemotherapy completion. tpCR was 35.6% in the MYL-1401O group (n = 59) and 40.3% in the TRZ (n = 77) group, p = 0.598. After controlling for clinically relevant variables, there was no significant difference in the odds of achieving tpCR in patients treated with TRZ versus MYL-1401O (OR 1.1, 95% CI 0.5–2.4, p = 0.850). tpCR rates were similar for patients treated with MYL-1401O compared to trastuzumab in our real world study of HER2+ neoadjuvant EBC and comparable to pivotal phase 3 trials. View Full-Text
Keywords: trastuzumab; biosimilar; MYL-1401O; HER2+; breast cancer; early stage trastuzumab; biosimilar; MYL-1401O; HER2+; breast cancer; early stage
MDPI and ACS Style

Yang, C.; Khwaja, R.; Tang, P.; Nixon, N.; King, K.; Lupichuk, S. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. Curr. Oncol. 2022, 29, 4224-4234. https://doi.org/10.3390/curroncol29060337

AMA Style

Yang C, Khwaja R, Tang P, Nixon N, King K, Lupichuk S. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. Current Oncology. 2022; 29(6):4224-4234. https://doi.org/10.3390/curroncol29060337

Chicago/Turabian Style

Yang, Charlie, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, and Sasha Lupichuk. 2022. "A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab" Current Oncology 29, no. 6: 4224-4234. https://doi.org/10.3390/curroncol29060337

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop